



November 7, 2013
FOR IMMEDIATE RELEASE:

Contact:
Daniel Lawson
Neuronetrix
1044 E. Chestnut St.
Louisville KY 40204
(502) 561-9040, x7003
dlawson@neuronetrix.com
www.neuronetrix.com

Neuronetrix Selected to Present at Prestigious Alzheimer's Research Conference

Louisville, KY (November 7, 2013) [Neuronetrix](http://www.neuronetrix.com) has been selected to present at the 6th Annual Conference on Clinical Trials for Alzheimer's Disease (CTAD) in San Diego, CA, on Nov 15, 2013. CTAD is the foremost conference where leading pharmaceutical companies discuss their strategic plans for drug development efforts to treat Alzheimer's disease.

Neuronetrix will present novel methods for analyzing complex electrophysiological measures of cognitive function. The data was collected as part of a large, multi-center clinical trial with over 200 subjects using the company's COGNISION™ System.

"Pharmaceutical companies demand sensitive, reliable, reproducible measures of the cognitive effects of treatment... COGNISION™ provides these measures," said KC Fadem, CEO of Neuronetrix. "This conference will give Neuronetrix the opportunity to showcase our game-changing technology."

About COGNISION™

The COGNISION™ System is a proprietary, neurodiagnostic device which enables objective assessments of cognitive function using a non-invasive technology called [event-related potentials](#) (ERP).

About Neuronetrix

Neuronetrix is a leading neurodiagnostic company focused on revolutionizing the diagnosis of patients with neurologic disorders by providing accurate and meaningful diagnostic information to physicians and pharmaceutical companies early in the disease process.

Information about Neuronetrix is available at <http://www.neuronetrix.com> or by contacting Daniel Lawson at dlawson@neuronetrix.com, or (502) 561-9040, x7003.

